{"id":"acp-204","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ACP-204 selectively activates M1 muscarinic acetylcholine receptors in the brain, which are involved in cognition, attention, and mood regulation. By increasing M1 receptor signaling, the drug aims to enhance acetylcholine-mediated neurotransmission, potentially improving cognitive deficits and negative symptoms in neuropsychiatric disorders. This mechanism is distinct from typical antipsychotics and may offer cognitive benefits in conditions like schizophrenia and Alzheimer's disease psychosis.","oneSentence":"ACP-204 is a muscarinic M1 receptor agonist that enhances cholinergic neurotransmission to improve cognitive and psychiatric symptoms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:08.126Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cognitive impairment associated with schizophrenia"},{"name":"Negative symptoms of schizophrenia"},{"name":"Psychosis in Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT07095465","phase":"PHASE3","title":"Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis","status":"ENROLLING_BY_INVITATION","sponsor":"ACADIA Pharmaceuticals Inc.","startDate":"2025-11-14","conditions":"Lewy Body Dementia Psychosis","enrollment":126},{"nctId":"NCT07029581","phase":"PHASE2","title":"Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis","status":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","startDate":"2025-08-06","conditions":"Lewy Body Dementia Psychosis","enrollment":180},{"nctId":"NCT06159673","phase":"PHASE2, PHASE3","title":"ACP-204 in Adults With Alzheimer's Disease Psychosis","status":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","startDate":"2023-11-14","conditions":"Alzheimer's Disease Psychosis","enrollment":1074},{"nctId":"NCT06194799","phase":"PHASE3","title":"ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study","status":"ENROLLING_BY_INVITATION","sponsor":"ACADIA Pharmaceuticals Inc.","startDate":"2024-04-23","conditions":"Alzheimer's Disease Psychosis","enrollment":752}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ACP-204 Tartrate"],"phase":"phase_3","status":"active","brandName":"ACP-204","genericName":"ACP-204","companyName":"ACADIA Pharmaceuticals Inc.","companyId":"acadia-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ACP-204 is a muscarinic M1 receptor agonist that enhances cholinergic neurotransmission to improve cognitive and psychiatric symptoms. Used for Cognitive impairment associated with schizophrenia, Negative symptoms of schizophrenia, Psychosis in Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}